"A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months, according "...
- Patient Information:
Details with Side Effects
DOSAGE AND ADMINISTRATION
Adults and Adolescents > 16 years of age
The recommended oral dose of EPIVIR (lamivudine) in HIV-1-infected adults and adolescents > 16 years of age is 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily, in combination with other antiretroviral agents. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen [see WARNINGS and PRECAUTIONS].
The recommended oral dose of EPIVIR (lamivudine) Oral Solution in HIV-1-infected pediatric patients 3 months to 16 years of age is 4 mg/kg twice daily (up to. a maximum of 150 mg twice a day), administered in combination with other antiretroviral agents.
EPIVIR (lamivudine) is also available as a scored tablet for HIV-1-infected pediatric patients who weigh ≥ 14 kg for whom a solid dosage form is appropriate. Before prescribing EPIVIR (lamivudine) Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow EPIVIR (lamivudine) Tablets, the oral solution formulation should be prescribed. The recommended oral dosage of EPIVIR (lamivudine) Tablets for HIV-1 -infected pediatric patients is presented in Table 1.
Table 1: Dosing Recommendations for EPIVIR (lamivudine) Tablets in Pediatric Patients
|Weight (kg)||Dosage Regimen Using Scored 150 mg Tablet|| Total |
|AM Dose||PM Dose|
|14 to 21||½ tablet (75 mg)||½ tablet (75 mg)||150 mg|
|> 21 to < 30||½ tablet (75 mg)||1 tablet (150 mg)||225 mg|
|≥ 30||1 tablet (150 mg)||1 tablet '(T50mB)||300 mg|
Patients With Renal Impairment
Dosing of EPIVIR (lamivudine) is adjusted in accordance with renal function. Dosage adjustments are listed in Table 2 [see CLINICAL PHARMACOLOGY].
Table 2: Adjustment of Dosage of EPIVIR (lamivudine) in Adults and Adolescents ( > 30 kg) in Accordance With Creatinine Clearance
| Creatinine Clearance |
|Recommended Dosage of EPIVIR|
|≥ 50||150 mg twice daily or 300mg once daily|
|30-49||150 mg once daily|
|15-29||150 mg first dose, then 100 mg once daily|
|5-14||150 mg first dose, then 50 mg once daily|
|< 5||50 mg first dose, then 25 mg once daily|
No additional dosing of EPIVIR (lamivudine) is required after routine (4-hour) hemodialysis or peritoneal dialysis.
Although there are insufficient data to recommend a specific dose adjustment of EPIVIR (lamivudine) in pediatric patients with renal impairment, a reduction in the dose and/or an increase in the dosing interval should be considered.
Dosage Forms And Strengths
- EPIVIR (lamivudine) Scored Tablets
150 mg, are white, diamond-shaped, scored, film-coated tablets debossed with "GX CJ7" on both sides.
- EPIVIR (lamivudine) Tablets
300 mg, are gray, modified diamond-shaped, film-coated tablets engraved with "GX EJ7" on one side and plain on the reverse side.
- EPIVIR (lamivudine) Oral Solution
A clear, colorless to pale yellow, strawberry-banana flavored liquid, contains 10 mg of lamivudine per 1 mL.
EPIVIR (lamivudine) Scored Tablets, 150 mg
White, diamond-shaped, scored, film-coated tablets debossed with "GX CJ7" on both sides.
Bottle of 60 tablets (NDC 0173-0470-01) with child-resistant closure.
EPIVIR (lamivudine) Tablets, 300 mg
Gray, modified diamond-shaped, film-coated tablets engraved with "GX EJ7" on one side and plain on the reverse side.
Bottle of 30 tablets (NDC 0173-0714-00) with child-resistant closure.
Store EPIVIR (lamivudine) Tablets at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
EPIVIR (lamivudine) Oral Solution, 10 mg/mL
A clear, colorless to pale yellow, strawberry-banana-flavored liquid, contains 10 mg of lamivudine in each 1 mL.
Plastic bottle of 240 mL (NDC 0173-0471-00) with child-resistant closure. This product does not require reconstitution.
Store in tightly closed bottles at 25°C (77°F) [see USP Controlled Room Temperature].
COMBIVIR, EPIVIR (lamivudine) , EPIVIR (lamivudine) -HBV, EPZICOM, and TRIZIVIR are registered trademarks of GlaxoSmithKline. ATRIPLA, EMTRIVA, and TRUVADA are trademarks of their respective owners and are not trademarks of GlaxoSmithKline. The makers of these brands are not affiliated with and do not endorse GlaxoSmithKline or its products. GlaxoSmithKline Research Triangle Park, NC 27709. FDA Rev date: 2/1/2008
Last reviewed on RxList: 3/11/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Epivir Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.